Skip to main content

HIV in 2022: An Overview of Current Epidemiology and Treatment of HIV

AAHIVM Course Banner
0.75 CEUs
HIV in 2022: An Overview of Current Epidemiology and Treatment of HIV

Course Description This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, and registered nurses; other healthcare providers, such as nutritionists, social workers, and case managers are also encouraged to attend.

Credit Dates April 26, 2022 - April 26, 2023

Estimated time to complete activity: 0.75 hours

This activity is jointly provided by the American Academy of HIV Medicine in collaboration with Postgraduate Institute for Medicine.

This activity is supported by independent educational grants from Gilead Sciences, Janssen Therapeutics, and ViiV Healthcare.
Educational Objectives
After completing this activity, the participant should be better able to:
  • Appraise the current epidemiology and spread of HIV in the United States and factors affecting the spread of HIV
  • Discuss when to initiate treatment for persons with HIV (PWA)
  • Differentiate between PWA with detectable and undetectable viral loads and how this contribute to new infections
  • Compare and contrast the recommended treatment regiments for PWA, especially newly the newly diagnosed
  • Assess future treatment options for HIV
  • Evaluate HIV-cure research
Target Audience 
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, and registered nurses; other healthcare providers, such as nutritionists, social workers, and case managers are also encouraged to attend.

Faculty
Xaviera Ortiz, MD
Physician - HIV Lead
LifeLong Ashby Health Center
Berkeley, California

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period April 26, 2022 through April 26, 2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 16798. Upon registering and completing the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement
Joint statement logoIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number JA4008162-9999-22-275-H02-P)

Type of Activity: Knowledge

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.